CHE Stock Recent News
CHE LATEST HEADLINES
Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.
The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemed (CHE) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $6.25 per share. This compares to earnings of $5.39 per share a year ago.
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2023, on Tuesday, February 27, 2024, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, February 28, 2024, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call.
Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.
Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 42nd Annual JPMorgan Healthcare Conference on Monday, January 8, 2024, at approximately 3:00 p.m. PST at the Westin St. Francis Hotel in San Francisco, CA. The presentation will be webcast live and can be accessed through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available approximately three hours after the live presentation and will.
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either DaVita HealthCare (DVA) or Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?
David Wagner, portfolio manager at Aptus Capital Advisors, joins 'Power Lunch' to discuss three stocks: Cintas, Chemed and CrowdStrike.
Investors with an interest in Medical - Outpatient and Home Healthcare stocks have likely encountered both DaVita HealthCare (DVA) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?